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Depression as a modifiable factor to decrease the risk of
dementia
OP Almeida1,2,3, GJ Hankey4,5, BB Yeap4,6, J Golledge7,8 and L Flicker2,4,9
Depression is an accepted risk factor for dementia, but it is unclear if this relationship is causal. This study investigated whether
dementia associated with depression decreases with antidepressant use and is independent of the time between exposure to
depression and the onset of dementia. We completed a 14-year longitudinal study of 4922 cognitively healthy men aged 71–89
years, and collected information about history of past depression, current depression and severity of depressive symptoms. Other
measures included use of antidepressants, age, education, smoking and history of diabetes, hypertension, coronary heart disease,
and stroke. The onset of dementia and death during follow-up was ascertained via the Western Australian Data Linkage System.
A total of 682 men had past (n= 388) or current (n= 294) depression. During 8.9 years follow-up, 903 (18.3%) developed dementia
and 1884 (38.3%) died free of dementia. The sub-hazard ratios (SHRs) of dementia for men with past and current depression were
1.3 (95% confidence interval (CI) = 1.0, 1.6) and 1.5 (95% CI = 1.2, 2.0). The use of antidepressants did not decrease this risk.
Compared to men with no symptoms, the SHRs of dementia associated with questionable, mild-to-moderate and severe depressive
symptoms were 1.2 (95% CI = 1.0, 1.4), 1.7 (95% CI = 1.4, 2.2) and 2.1 (95% CI = 1.4, 3.2), respectively. The association between
depression and dementia was only apparent during the initial 5 years of follow-up. Older men with history of depression are at
increased risk of developing dementia, but depression is more likely to be a marker of incipient dementia than a truly modifiable
risk factor.
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INTRODUCTION
Symptomatic treatments for dementia remain limited in scope
and efficacy,1 and despite significant financial investment, there is
no cure in sight.2 However, accumulating epidemiological data
has revealed several potentially modifiable risk factors, offering
hope that prevention is possible. Education, diabetes, hyperten-
sion, obesity, physical inactivity, smoking and depression account
for ~ 30% of Alzheimer’s disease cases so that risk-modifying
interventions could potentially reduce its prevalence worldwide.3
Emerging trial data indicate that this may be a strategy worth
pursuing.4–6
Norton et al.3 estimated that 5–11% of Alzheimer’s disease
cases could be attributed to depression. It means that the
prevalence of dementia in the population would be reduced by
the same amount if depression could be prevented or adequately
treated. The personal and socioeconomic benefits of such a
reduction would be substantial.7 This assumes, of course, that
depression causes dementia. The most compelling way of
demonstrating causality would be by means of a randomised
controlled trial, but such a trial would not be ethical or feasible.
Observational data consistently show that depression increases
the risk of incident dementia,8 and there is tentative evidence for
a dose-effect modulating this relationship,9,10 particularly when
the severity of symptoms increases over time.11,12 In addition,
older adults with depression show improved cognitive performance
after successful treatment,13,14 and there is some evidence that
depression may lead to loss of hippocampal volume, particularly
when symptoms are persistent.15 Finally, new observational data
suggest that severe depression may contribute to accelerate
cellular ageing, as measured by telomere length.16 Taken together,
these findings imply that the association between depression and
cognitive impairment is both consistent and plausible.
We used data from the Health In Men Study to investigate
whether depression is likely to be causally related to incident
dementia. On the basis of existing evidence, we hypothesised that
the risk of incident dementia would be associated with: (1) past and
current depression, (2) increasing severity of depressive symptoms
and (3) lower exposure to antidepressant treatment. Finally, we
hypothesised that the risk of dementia associated with depression
would be independent of the duration of the follow-up period. This
latter hypothesis is based on the premise that depression is not
simply an early prodromal manifestation of dementia.
MATERIALS AND METHODS
Study design and setting
Health In Men Study is a community-based cohort study based in Western
Australia.
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Participants
We used the Australian Electoral Roll to recruit a sample of 12 203 men
aged 65–84 years living in Perth in 1996—voting is compulsory in
Australia.17 During a second wave of assessments between 2001 and 2004,
5514 participants provided information about depressive symptoms and
past history of depression (details below)—592 of them had documented
history of dementia (details below) or cognitive impairment (Mini-Mental
State Examination scoreo24).18 Hence, the study sample consisted of
4922 men aged 71–89 years who were free of dementia/cognitive
impairment. They were followed until the onset of dementia, death or up
to 30 June 2015, whichever occurred first.
The study was conducted in accordance with the principles expressed in
the Declaration of Helsinki and was approved by the Ethics Committees of
the University of Western Australia and of the Department of Health of
Western Australia. All men offered written informed consent.
Outcome of interest
Dementia was the primary endpoint of the study, and its onset was
established through the Western Australian Data Linkage System. Western
Australian Data Linkage System brings together data for all health contacts
with the hospital system of Western Australia, including emergency
departments, elective and non-elective admissions, mental health out-
patient services, community aged care services, as well as cancer and
death registries.19 Each occasion of service triggers the recording of the
respective date and associated primary and up to 20 secondary diagnoses,
which are coded according to the International Classification of Diseases
10th edition. The following codes indicated the diagnosis of dementia: F00,
F01, F02, F03, G30, G31.0, G31.1 and G31.83. We did not examine individual
types of dementia because ‘unspecified dementia’ was the most frequently
recorded diagnosis. We used Western Australian Data Linkage System to
exclude following up of men with a recorded diagnosis of dementia before
2001–2004, as described above. From 1 January 1979 to the 30 June 1999,
the following International Classification of Diseases 9th edition codes
were used for the diagnosis of dementia: 290, 294.1, 294.2, 331.0, 331.1,
331.2 and 331.82.
Other study measures
At the 2001–2004 assessment, we asked participants whether they had
‘ever been treated for an emotional or nervous illness such as depression’
(possible answers: yes/no), and considered that past depression was
present when men answered in the affirmative. Participants also
completed the short version of the Geriatric Depression Scale (GDS-15),
and we considered that clinically significant symptoms of depression were
present when the total score was 7 or greater.20 As previously described,21
participants were also grouped according to the severity of depressive
symptoms: none (GDS-15= 0), questionable (GDS-15 between 1 and 4),
mild to moderate (GDS-15 between 5 and 9) and severe (GDS-15⩾ 10).
At this same point in time, participants were asked to provide a
complete list of the medications they had been using on a regular basis. All
medications were coded according to the Anatomical Therapeutic
Chemical Classification System.22 Code N06A indicates the use of
antidepressants. The codes N06AA, N06AB, N06AF and N06AX are the
codes used for tricyclic, selective serotonin reuptake inhibitors, mono-
amine oxidase inhibitors (non-selective) and other antidepressants,
respectively.
Participants provided information about their age (in years), date of
birth, educational achievement (completed high school vs incomplete high
school), smoking (never, past or current) and medical history. In addition,
we asked them whether a doctor had ever told them that they had
diabetes, hypertension, coronary heart disease or a stroke (yes/no).
Statistical analyses
We used the statistical package Stata 14.2 (StataCorp, College Station, TX,
USA) to manage and analyse the data. We stratified the study population
according to the history of depression (never, past only and current). We
examined the distribution of study measures (counts and proportions) for
the population and for depression groups, and calculated the odds ratio
and respective 95% confidence interval (95% CI) relative to men who had
never been depressed. As death was a competing risk of dementia, we
used competing risk Cox regression models. The risk estimates are
expressed as sub-hazard ratios (SHRs) and 95% CI. We repeated these same
analyses by subsequently taking into account the interaction between the
depression group and use of antidepressants. We then completed a series
of planned analyses to investigate the effect of time of follow-up on the
risk of dementia. We did this by limiting the analyses described above to a
short (o5 years), medium (5 to up 10 years) and long (⩾10 years) duration
of follow-up. We also investigated the SHR of dementia associated with
individual groups of antidepressants: selective serotonin reuptake inhibitor,
tricyclic, monoamine oxidase inhibitors (non-selective) and others. We
calculated crude and adjusted associations—for the latter, we included in
the models study measures associated with Po0.1. Finally, we calculated
the annual rate of dementia per 1000 person-years for men with and
without history of past or current depression. Alpha was set at 5% and all
tests reported were two-tailed.
Computational codes used in the analysis of the data are available from
the corresponding author upon request.
Sample size
The annual incidence proportion of dementia is about 53 new cases per
1000 persons.23 Using the Schoenfeld method, we estimated that the
study would have 80% power to detect a hazard ratio of 1.3 or greater for a
sample of 180 men with current depression and 180 men with past
depression. As 38% of the sample died during follow-up, the number of
participants with current and past depression would have to be at least
250 each to allow for censoring. The study included 294 men with current
depression and 388 with past depression.
RESULTS
This study included 4922 men free of dementia or clinically
significant cognitive impairment. Their mean age was 77.2 years (s.
d. = 3.7), and their characteristics at the start of follow-up are
summarised in Table 1.
Participants were followed, on average, for 8.9 years (range:
0.02–14.3 years). During this time, 903 men received the diagnosis
of dementia (18.3%) and 1884 died free of dementia (38.3%). The
adjusted SHR of dementia among men who had ever been
depressed (past or current) was 1.3 (95% CI = 1.2, 1.7), and for men
with a past history of depression only was 1.3 (95% CI = 1.0, 1.6)
and for men with current depression (with or without past
depression) was 1.5 (95% CI = 1.2, 2.0; Figure 1). 302 men (6.1%)
were using antidepressants at the time of the assessment. Figure 2
shows the SHR of dementia (and respective 95% CI) according
to history of depression and antidepressant use. The use of
antidepressants did not decrease the risk of dementia (Figure 2).
The interaction term between antidepressant use and history
of depression did not reach statistical significance (P= 0.120).
All analyses were adjusted for age, and history of diabetes
and stroke (other variables made no significant contribution to
the model).
We found that 1081 (22.0%) men had no depressive symptoms,
3171 (64.4%) had questionable symptoms, 509 (10.3%) had mild-
to-moderate symptoms and 106 (2.1%) had severe symptoms.
Fifty-five (1.1%) participants returned missing data for at least one
GDS-15 item. Compared with men with no symptoms, the SHRs of
dementia were 1.2 (95% CI = 1.0, 1.4), 1.7 (95% CI = 1.4, 2.2) and 2.1
(95% CI = 1.4, 3.2) for participants with questionable, mild-to-
moderate and severe depressive symptoms. Similarly, the respec-
tive adjusted SHRs were 0.2 (95% CI = 0.0, 1.6) for men with no
depressive symptoms on antidepressants, 1.1 (95% CI = 0.9, 1.4) for
men with questionable depressive symptoms not on antidepres-
sants, 1.4 (95% CI = 0.9, 2.0) for men with questionable depressive
symptoms on antidepressants, 1.6 (95% CI = 1.2, 2.1) for men with
mild-to-moderate depressive symptoms who were not on anti-
depressants, 2.5 (95% CI = 1.6, 3.8) for men with mild-to-moderate
depressive symptoms on antidepressants, 1.5 (95% CI = 0.9, 2.5) for
men with severe depressive symptoms not on antidepressants
and 4.8 (95% CI = 2.3, 9.8) for men with severe depressive
symptoms on antidepressants. The interaction between the
severity of depressive symptoms and the use of antidepressants
on dementia risk was statistically significant (Po0.05). All analyses
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were adjusted for age, and history of diabetes and stroke (all other
measures made no obvious contribution to the model).
The number of men who developed dementia during the initial
5 years of follow-up was 234, from 5 to 10 years 516 and after 10
years 153. We stratified the data according to time of follow-up to
investigate whether the risk of dementia associated with
depression varied according to the duration of the follow-up
period (Figure 3). All analyses were adjusted for age, and history of
diabetes and stroke.
We then completed a series of post hoc analyses to investigate
the contribution of individual antidepressant classes to dementia
risk. The independent SHR of dementia associated with anti-
depressant use was 1.3 (95% CI = 1.0, 1.7). The use of selective
serotonin reuptake inhibitors, tricyclics, monoamine oxidase
inhibitors (non-selective) and other antidepressants was reported
by 127 (2.6%), 132 (2.7%), 8 (0.2%) and 50 (1.0%) men. The SHRs ofT
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Figure 1. The figure shows the proportion of men remaining free of
dementia over 14 years according to history of depression at the
start of the follow-up period. The sub-hazard ratios of dementia
associated with past and with current depression were 1.4 (95%
confidence interval (CI)= 1.1, 1.7) and 1.8 (95% CI= 1.4, 2.3).
Figure 2. The figure shows the risk ratio of dementia over a follow-
up period of up to 14 years according to history of depression and
exposure to antidepressants at study entry (reference: men with no
history of depression who were not using antidepressants). The
diamonds show the sub-hazard ratio (SHR) of dementia and the
whiskers the 95% confidence interval of the SHR. Blue and red
diamonds show ratios for men not using and using antidepressants,
respectively. The presentation was stratified into no, past and
current depression.
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dementia associated with the use of selective serotonin reuptake
inhibitors, tricyclics, monoamine oxidase inhibitors (non-selective)
and other antidepressants were 1.4 (95% CI = 0.8, 2.1), 1.0 (95%
CI = 0.7, 1.5), 1.2 (95% CI = 0.3, 5.0) and 2.2 (95% CI = 1.3, 3.8). These
analyses were adjusted for age, history of diabetes and stroke, and
history of depression (past or current).
The annual rates of dementia per 1000 person-years for men
without depression were 3.0 (95% CI = 1.3, 6.5), 5.6 (95% CI = 4.4,
7.2), 17.8 (95% CI = 15.8, 20.1) and 41.1 (95% CI = 37.3, 45.4) for
ages 70–75, 75–80, 80–85 and 485 years. Similarly, for men with
history of past or current depression, the respective rates were 3.1
(95% CI = 0.4, 22.3), 19.2 (95% CI = 13.5, 27.3), 34.2 (95% CI = 27.0,
43.4) and 47.0 (95% CI = 36.8, 60.1). There were 234 incidence
cases of dementia during the first 5 years of follow-up (169 never
depressed, 26 with history of past depression and 39 with current
depression), 516 between 5 and 10 years (436 never depressed, 48
with history of past depression and 32 with current depression)
and 153 after 10 years (133 never depressed, 12 with history of
past depression and 8 with current depression).
DISCUSSION
The results of this 14-year longitudinal study of older men
confirmed that history of depression is associated with increased
risk of incident dementia, and that this risk is particularly high
among men with clinically significant symptoms of depression at
the start of the follow-up period. We also found that there was a
graded association between the severity of depressive symptoms
and the risk of dementia, with the risk being more pronounced for
men with severe depression. Contrary to our expectations, the use
of antidepressants did not decrease the risk of dementia
associated with depression. Finally, we found that the association
between depression and incident dementia was largely due to
cases of dementia accrued during the first 5 years of follow-up,
after which the association between depression and incident
dementia disappeared.
This project has the merit of having had access to a large and
well-characterised cohort of older men and a suitably long follow-
up period to ascertain the onset of dementia. Another important
feature of a longitudinal study such as this is that follow-up data
were available through Western Australian Data Linkage System
for all participants, as the internal and external migratory
movement of older Western Australians is negligible.24 The
diagnosis of dementia itself, although not derived from structured
clinical, neuropsychological and imaging investigations, included
the best available information retrieved from hospital and
community services. As the rates of dementia that we observed
in our sample were largely consistent with those reported by
others using different methods,25 we trust that our approach was
appropriate to identify most cases of dementia. Nonetheless, we
accept that some cases of dementia may have not been detected.
If the distribution of these cases was random, some loss of power
would have ensued, but not bias. It is conceivable, however, that
the detection of cases may have occurred more frequently among
men with depression because they come to medical attention
more frequently than men without depression26—this would have
increased the opportunity for the diagnosis of dementia to be
established. Such bias could have inflated the number of cases of
dementia associated with depression, so that the real association
between depression and dementia could be less pronounced than
our numbers suggest.
We also acknowledge that our assessment of depression was not
based on a gold standard structured clinical interview, but on self-
report and a depression scale. However, both approaches have
good face-validity.20,27 Perhaps, the most obvious limitation of our
study design was the lack of information about the onset and
recurrence of depressive symptoms and the use of antidepressants
during follow-up. A considerable number of depression cases in
later life are due to recurrence, but incident cases do occur
particularly in people aged in their 80s.28 Such new false-negative
cases of depression would have increased the chance of type II
error and, potentially, would have led to an underestimation of the
effect size of the association between depression and incident
dementia. In addition, the lack of information about the use of
medications during follow-up and their use as maintenance therapy
creates uncertainty about the potential effect of antidepressants in
modifying dementia risk. Confounding by indication is another
issue that should be considered, as antidepressants may have been
prescribed preferentially to the more severe cases of depression.
However, it is helpful to note that only ~ 30% of antidepressant
users suffer from depression (past or current),29 which together
with our finding that the use of antidepressants by men without
depression had no observable beneficial effect on the risk of
dementia, suggest that the overall results of our study are likely to
offer an acceptable, although tentative, estimate of risk associated
with depression and antidepressant use.
Another potential caveat of the study is the lack of information
about the timeline associated with history of past depression. It is
conceivable that depression with onset in early or mid-life could
contribute to modulate the risk of dementia later in life, whereas
depression arising in older age may be more frequently an early
manifestation of an underlying neurodegenerative process. As we
did not have access to information about the age of onset of
symptoms, we cannot be entirely certain that depression with
early and late onset do not differ in their relationship with
dementia risk.
It is also important to consider the issue of bias associated with
competing risks. When assessing an event that occurs late in life
(such as dementia),25 premature death will remove from the
sample people who could have developed dementia later, if they
had survived. This may be particularly important in this case, as
people with depression die earlier than those without.21 The early
censoring of older men with depression could have led to a biased
lower risk of dementia among older men with history of
depression. For this reason, and in contrast with previous
studies,8 we used a competing risk Cox regression model that
took into account the competing risk of death and the potential
confounding associated with the overlapping risk factors for
depression and dementia.3,30 This approach to the analysis of the
data enhances our confidence that our findings are most likely
valid, although they are limited to men and cannot be generalised
to women. Furthermore, we concede that some unmeasured
Figure 3. The figure shows the risk ratio of dementia according to
time of follow-up (⩽5, 5–10 and ⩾ 10). The diamonds show the sub-
hazard ratio of dementia and the whiskers show the 95% confidence
interval of the sub-hazard ratio. The blue and red diamonds depict
men with past and current depression at study entry, respectively.
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factors, such as apolipoprotein E genotype and lipids, were not
taken into account in our analyses, although findings from other
relevant studies are consistent with ours.11,12,31
Like previous studies,8 we found that history of past or current
depression increased the risk of dementia, but this relationship is
unlikely to be causal. Treatment with antidepressants, despite less
than ideal efficacy,32,33 would have been expected to reduce the
risk of dementia associated with depression—that did not occur.
Moreover, the association between depression and dementia was
limited to the first few years of follow-up, suggesting that
depression may represent a prodromal manifestation of dementia
rather than one of its causes. Data from the Rotterdam Study are
consistent with this interpretation: 4393 older adults (mean age 73
years) were followed for up to 13.7 years for incident dementia,
which was diagnosed according to the Diagnostic and Statistical
Manual for Mental Disorders 3rd edition revised criteria.34 They
found that 13% of them developed dementia and that depression
increased the hazard of dementia by ~ 20% by 2 and 5 years, but
not beyond that time point.34 In fact, depressive symptoms are
common antecedents of several neurodegenerative disorders35,36
and could be seen as an early non-specific behavioural
manifestation of a brain under physiological stress. If that is the
case, depression in later life may be better understood, at least in
some cases, as an early sign of dementia rather than a factor that
can be potentially modified to decrease future risk. There is
evidence from longitudinal studies of depression that this may
indeed be the case.13,14 However, our data cannot dismiss the
possibility that depressive disorder with onset in earlier life may be
a potentially modifiable risk factor for dementia.
In conclusion, our findings indicate that older men with the
history of depression are at increased risk of developing dementia,
although depression in later life is more likely to be a marker of
incipient dementia than a truly modifiable risk factor. Older people
with depression may be better viewed as potential targets of
indicated prevention strategies,37 rather like people with mild
cognitive impairment.
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